Symphogen, a Denmark-based developer of antibody therapeutics to treat cancer and disease, has added €41m ($54m) to its previous round.
Novo, a $20bn quasi-corporate venturing investment company wholly owned by the Novo Nordisk Foundation, and local pension fund PKA each invested €20m, with Danica Pension co-investing.
Henrik Gürtler, chief executive of Novo, said: “It is important to understand the significance of the investments of Danica Pension and PKA.
“This is Danica Pension’s first active investment in Symphogen, where they are…
